|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/09/22 Y-mAbs Therapeutics, Inc. 10-Q 3/31/22 85:7.2M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.13M
5: EX-10.10 Material Contract HTML 71K
6: EX-10.11 Material Contract HTML 41K
2: EX-10.7 Material Contract HTML 37K
3: EX-10.8 Material Contract HTML 67K
4: EX-10.9 Material Contract HTML 48K
7: EX-31.1 Certification -- §302 - SOA'02 HTML 29K
8: EX-31.2 Certification -- §302 - SOA'02 HTML 29K
9: EX-32.1 Certification -- §906 - SOA'02 HTML 25K
10: EX-32.2 Certification -- §906 - SOA'02 HTML 25K
16: R1 Document and Entity Information HTML 77K
17: R2 Consolidated Balance Sheets HTML 120K
18: R3 Consolidated Balance Sheets (Parenthetical) HTML 36K
19: R4 Consolidated Statements of Net Income (Loss) and HTML 90K
Comprehensive Income (Loss)
20: R5 Consolidated Statements of Changes in HTML 69K
Stockholders' Equity
21: R6 Consolidated Statements of Cash Flows HTML 95K
22: R7 Organization and Description of Business HTML 26K
23: R8 Basis of Presentation HTML 31K
24: R9 Summary of Significant Accounting Policies HTML 81K
25: R10 Product Revenue HTML 54K
26: R11 Net Loss Per Share HTML 47K
27: R12 Inventories HTML 57K
28: R13 Intangible Assets HTML 26K
29: R14 Accrued Liabilities HTML 42K
30: R15 License Agreements and Commitments HTML 134K
31: R16 Stockholders' Equity HTML 33K
32: R17 Share-Based Compensation HTML 89K
33: R18 Related Party Transactions HTML 26K
34: R19 Income Taxes HTML 29K
35: R20 Other Benefits HTML 25K
36: R21 Gain From Sale of Priority Review Voucher HTML 26K
37: R22 Subsequent Events HTML 26K
38: R23 Summary of Significant Accounting Policies HTML 110K
(Policies)
39: R24 Summary of Significant Accounting Policies HTML 60K
(Tables)
40: R25 Product Revenue (Tables) HTML 48K
41: R26 Net Loss Per Share (Tables) HTML 45K
42: R27 Inventories (Tables) HTML 56K
43: R28 Accrued Liabilities (Tables) HTML 41K
44: R29 License Agreements and Commitments (Tables) HTML 122K
45: R30 Share-Based Compensation (Tables) HTML 83K
46: R31 BASIS OF PRESENTATION - Accumulated deficit HTML 26K
(Details)
47: R32 BASIS OF PRESENTATION - Secondary public offering HTML 36K
(Details)
48: R33 BASIS OF PRESENTATION - Cash and cash equivalents HTML 25K
(Details)
49: R34 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 31K
Concentration of Credit Risk (Details)
50: R35 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair HTML 41K
Value Measurement (Details)
51: R36 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 24K
Operating Leases (Details)
52: R37 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 27K
Revenue and Segment (Details)
53: R38 PRODUCT REVENUE - Discounts and Allowances HTML 60K
(Details)
54: R39 PRODUCT REVENUE - Concentrations (Details) HTML 34K
55: R40 NET LOSS PER SHARE - Basic and diluted (Details) HTML 50K
56: R41 NET LOSS PER SHARE - Anti-dilutive securities HTML 25K
(Details)
57: R42 Inventories (Details) HTML 39K
58: R43 Intangible Assets (Details) HTML 42K
59: R44 Accrued Liabilities (Details) HTML 37K
60: R45 LICENSE AGREEMENTS AND COMMITMENTS - License HTML 63K
Agreements (Details)
61: R46 LICENSE AGREEMENTS AND COMMITMENTS - Other HTML 41K
agreements (Details)
62: R47 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 63K
agreements (Details)
63: R48 LICENSE AGREEMENTS AND COMMITMENTS - Lease costs HTML 32K
(Details)
64: R49 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 40K
maturities (Details)
65: R50 LICENSE AGREEMENTS AND COMMITMENTS - Lease term HTML 27K
and discount rate (Details)
66: R51 STOCKHOLDERS' EQUITY - Authorized, Common and HTML 42K
Preferred Stock (Details)
67: R52 STOCKHOLDERS' EQUITY - Stock grant agreements with HTML 57K
non-employees (Details)
68: R53 STOCKHOLDERS' EQUITY - Issuance of common stock HTML 36K
(Details)
69: R54 SHARE-BASED COMPENSATION - 2015 Plan (Details) HTML 33K
70: R55 SHARE-BASED COMPENSATION - 2018 Plan (Details) HTML 43K
71: R56 SHARE-BASED COMPENSATION - Stock-based HTML 39K
compensation expense (Details)
72: R57 SHARE-BASED COMPENSATION - Stock option activity HTML 57K
(Details)
73: R58 SHARE-BASED COMPENSATION - Stock option HTML 30K
unrecognized compensation (Details)
74: R59 SHARE-BASED COMPENSATION - Restricted Stock Unit HTML 53K
Activity (Details)
75: R60 Related Party Transactions (Details) HTML 37K
76: R61 INCOME TAXES - Loss before income taxes (Details) HTML 33K
77: R62 INCOME TAXES - Uncertain tax positions (Details) HTML 27K
78: R63 Other Benefits (Details) HTML 30K
79: R64 Gain From Sale of Priority Review Voucher HTML 36K
(Details)
80: R65 Subsequent Events (Details) HTML 31K
83: XML IDEA XML File -- Filing Summary XML 144K
81: XML XBRL Instance -- ymab-20220331x10q_htm XML 1.38M
82: EXCEL IDEA Workbook of Financial Reports XLSX 86K
12: EX-101.CAL XBRL Calculations -- ymab-20220331_cal XML 135K
13: EX-101.DEF XBRL Definitions -- ymab-20220331_def XML 489K
14: EX-101.LAB XBRL Labels -- ymab-20220331_lab XML 1.14M
15: EX-101.PRE XBRL Presentations -- ymab-20220331_pre XML 841K
11: EX-101.SCH XBRL Schema -- ymab-20220331 XSD 174K
84: JSON XBRL Instance as JSON Data -- MetaLinks 349± 505K
85: ZIP XBRL Zipped Folder -- 0001558370-22-007851-xbrl Zip 324K
Certain information (marked as [***]) has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
Exhibit 10.7
|
AMENDMENT NO. 2 to LICENSE AGREEMENT DATED AS OF MARCH 18, 2021 between MEMORIAL SLOAN-KETTERING CANCER CENTER and Y-MABS THERAPEUTICS, INC. DATED: FEBRUARY 11, 2022 |
Certain information (marked as [***]) has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
AMENDMENT NO. 2 TO LICENSE AGREEMENT
This Amendment No. 2 dated February 11, 2022 (the “Amendment”), is made to that certain License Agreement dated August 20, 2015, as amended on March 18, 2021 (the “License Agreement”), by and between Memorial Sloan Kettering Cancer Center (“MSK”), a New York not-for-profit corporation, with its principal offices at 1275 York Avenue, New York, NY 10065; and Y-mAbs Therapeutics, Inc., a Delaware corporation, with its principal offices located at 230 Park Avenue, Suite 3350, New York, NY 10169 (“LICENSEE”). MSK and LICENSEE are sometimes referred to herein singly as a “Party” and collectively as “Parties”.
All capitalized terms not otherwise defined herein shall have the meanings assigned to them in the License Agreement.
W I T N E S S E T H
WHEREAS, MSK and LICENSEE have previously entered into the License Agreement, pursuant to which, among other things, MSK has granted licenses under certain Licensed Rights to LICENSEE;
WHEREAS, MSK has generated a new invention covering a method for [***] (“[***] Invention”);
WHEREAS, MSK desires to have the [***] Invention utilized in the public interest and is willing to grant licenses to its interests thereunder;
WHEREAS, LICENSEE desires to obtain an exclusive license to MSK’s interest in the patents directed to the [***] Invention; and
WHEREAS, upon the terms and conditions set forth herein, MSK desires to grant, and LICENSEE desires to accept, a license under certain of its interests in the Modak Invention.
NOW THEREFORE, in consideration of the mutual premises and mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:
ARTICLE 1- AMENDMENT
1.1Exhibit A to the License Agreement is hereby supplemented by Supplement 1 to Exhibit A, which is annexed to this Amendment as Attachment 1.
1.2 The following is added as a new last sentence of Article 7.1:
“LICENSEE shall reimburse MSK in the amount of up to $[***] for all historic patent costs relating to the patents and patent applications added to the License Agreement by Amendment No. 2 thereto, within [***] days of the effective date of Amendment No. 2 or, for patent costs that have been incurred but not billed to MSK prior to the effective date of the Amendment No. 2, LICENSEE shall pay within [***] days of receiving in invoice from MSK. ”
ARTICLE 2– MISCELLANEOUS
Certain information (marked as [***]) has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
2.1The Parties agree that, apart from the parts specifically amended hereunder, all terms and conditions of the License Agreement remain and shall remain in full force and effect.
IN WITNESS WHEREOF, each of the Parties hereto has caused this Amendment to be executed by its duly authorized representative, all as of the day and year first written above.
| s/s
Greg Raskin |
| MEMORIAL SLOAN KETTERING CANCER CENTER By s/s Greg Raskin |
| Y-MABS THERAPEUTICS, INC. By /s/ Thomas Gad By /s/ Claus Møller |
| |
Certain information (marked as [***]) has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
Attachment 1
Supplement 1 to Exhibit A
ANTIBODY PATENT RIGHTS
The following patents and patent applications are hereby included in the definition of Antibody Patent Rights:
IP Track Code | Intellectual Property Title | Attorney Ref | Attorney Firm | Application No. | Country of Filing | Status | Inventors |
[***] | [***] | | | [***] | [***] | [***] | [***] |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/9/22 | 8-K | ||
| For Period end: | 3/31/22 | |||
| 2/11/22 | 8-K | |||
| 3/18/21 | ||||
| 8/20/15 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/29/24 Y-mAbs Therapeutics, Inc. 10-K 12/31/23 101:10M Toppan Merrill Bridge/FA 3/30/23 Y-mAbs Therapeutics, Inc. 10-K 12/31/22 106:10M Toppan Merrill Bridge/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/26/18 Y-mAbs Therapeutics, Inc. 8-K:5,7,9 9/25/18 4:284K Toppan Merrill/FA 8/24/18 Y-mAbs Therapeutics, Inc. S-1 31:12M Toppan Merrill-FA |